Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance
TAIPEI, Aug. 6, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that the Taiwan Food and Drug Administration (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.